Apabetalone (RVX-208) decreases atherogenic, thrombotic and inflammatory mediators in vitro and in plasma of patients with cardiovascular disease (CVD). (September 2016)

Record Type:
Journal Article
Title:
Apabetalone (RVX-208) decreases atherogenic, thrombotic and inflammatory mediators in vitro and in plasma of patients with cardiovascular disease (CVD). (September 2016)
Main Title:
Apabetalone (RVX-208) decreases atherogenic, thrombotic and inflammatory mediators in vitro and in plasma of patients with cardiovascular disease (CVD).
Authors:
Wong, N.
Kulikowski, E.
Wasiak, S.
Gilham, D.
Calosing, C.
Laura, T.
Halliday, C.
Johansson, J.
Sweeney, M.
Abstract:
Is Part Of:
Atherosclerosis. Volume 252(2016)
Journal:
Atherosclerosis
Issue:
Volume 252(2016)
Issue Display:
Volume 252, Issue 2016 (2016)
Year:
2016
Volume:
252
Issue:
2016
Issue Sort Value:
2016-0252-2016-0000
Page Start:
e245
Page End:
Publication Date:
2016-09
Subjects:
Arteriosclerosis -- Periodicals
Electronic journals
616.136
Journal URLs:
http://www.sciencedirect.com/science/journal/00219150 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/00219150 ↗
http://www.elsevier.com/journals ↗
DOI:
10.1016/j.atherosclerosis.2016.07.042 ↗
Languages:
English
ISSNs:
0021-9150
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - 1765.874000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
21867.xml